Results 141 to 150 of about 22,314 (175)

Efficacy and safety of mini-cvd combined with venetoclax and azacitidine in philadelphia chromosome-negative acute leukemia of ambiguous lineage: a single-center retrospective study. [PDF]

Ann Hematol
Li Y, Shang Y, Liu K, Liu Y, Lin D, He J, Li J, Zeng Y, Wei H, Yan Z, Mi Y.   +10 more
europepmc   +1 more source

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. [PDF]

Blood Adv
Montesinos P, Marchione DM, Recher C, Heuser M, Vives S, Zarzycka E, Wang J, Riva M, Calado RT, Schuh AC, Yeh SP, Tron AE, Hui J, Gianolio DA, Choe S, Patel P, De Botton S, DiNardo CD, Döhner H.   +18 more
europepmc   +1 more source

Monitoring Variant Allele Fraction in VEXAS Syndrome: A Comparison of Digital PCR and Next-Generation Sequencing. [PDF]

EJHaem
Exposito-Bey A, Montes-Cano MA, Payán-Pernía S, García-Lozano JR, González-Escribano MF.   +4 more
europepmc   +1 more source

Combined anti-tumor effects of metformin and azacitidine in breast cancer cells. [PDF]

BMC Cancer
Hosseini SS, Askari N, Yaghoobi MM.
europepmc   +1 more source

Cancer treatment in the era of targeted therapy: the March is on! [PDF]

, 2011
Chim, JCS
core   +2 more sources

Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learning. [PDF]

Cell Rep Med
Jin P, Wang D, Shen J, Jin Q, Zhang H, Liu X, He M, Jin W, Li Y, Dong F, Jin F, Yang Y, Zheng R, Wang S, Guo J, Li S, Liu D, Yan Z, Jin C, Xu B, Guo W, Zhu H, Zhang Y, Jin Z, Wang K.   +24 more
europepmc   +1 more source

Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. [PDF]

Trials
Yan H, Huang X, Wu P, Deng C, Li M, Lai P, Du X, Weng J.   +7 more
europepmc   +1 more source

Novel approaches to the use of hypomethylating agents in myeloid malignancies. [PDF]

Epigenomics
Cheng J, O'Connell C, O'Connell C.
europepmc   +1 more source

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. [PDF]

Leukemia
Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V.   +13 more
europepmc   +1 more source

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AML. [PDF]

Future Oncol
Nier S, Pelouchova J, Hills R, Salek S, Derrien H, Chatin S, De La Bigne AM, Vives S, Recher C, Döhner H, Venditti A, Vyas P.   +11 more
europepmc   +1 more source